In this study, we demonstrate a reduction in TNBC tumor burden by targeting a novel pathway involving α7 nicotinic acetylcholine receptor (CHRNA7) using AR-R17779, a small molecule agonist that is highly specific for CHRNA7.5–7. Here, CHRNA7 is linked to neoplasm.